Eicosapentaenoic acid alleviates fibromyalgia-like pain by modulating microglia, astrocytes, and toll-Like receptor 4 signaling in the mice cerebellum.

Fibromyalgia is a challenging condition characterized by widespread body pain, often accompanied by sleep problems, mood changes, and depression. A recent study explored whether eicosapentaenoic acid (EPA), an omega-3 fatty acid found in fish oil, could help relieve fibromyalgia pain. Researchers used mice to model fibromyalgia-like symptoms by exposing them to intermittent cold stress, which successfully induced pain sensitivity. They found that mice with fibromyalgia-like symptoms had significantly increased sensitivity to both touch and heat. When these mice received oral EPA supplementation, their pain responses improved dramatically. The study revealed that EPA works by calming overactive immune cells in the cerebellum (a brain region involved in pain processing) and reducing inflammatory signaling pathways, particularly those involving TLR4 receptors. Mice with fibromyalgia had elevated levels of pain-related substances and inflammatory markers in their brains, which decreased after EPA treatment. This research suggests that EPA supplementation may offer a nutritional approach to managing fibromyalgia pain by addressing underlying neuroinflammation. For patients exploring complementary approaches to fibromyalgia management, this adds to growing evidence supporting omega-3 fatty acids as part of an integrative treatment plan. While this study provides promising preliminary data, patients should discuss EPA supplementation with their healthcare providers to determine appropriate dosing and ensure it complements their overall treatment strategy. Those considering acupuncture for fibromyalgia should seek treatment from a licensed and board-certified acupuncturist experienced in pain management.

This study investigated EPA's effects on fibromyalgia-like pain in a murine model induced by intermittent cold stress (ICS). Researchers evaluated mechanical and thermal pain thresholds using von Frey and Hargreaves' tests. ICS mice demonstrated significant hyperalgesia (mechanical threshold: 2.01±0.11g; thermal latency: 4.09±0.34s), which improved with oral EPA administration (3.68±0.13g and 7.89±0.3s, respectively). Mechanistic analysis revealed elevated microglia/astrocyte markers (HMGB1, S100B) and upregulated TLR4 signaling pathways in cerebellar regions CB5-7 of FM mice. EPA supplementation effectively reduced these neuroinflammatory markers and associated nociceptive signals. EPA levels were depleted in FM mice but normalized following oral supplementation. Clinical implications suggest EPA may serve as an adjunctive nutritional intervention for fibromyalgia management by modulating neuroinflammation through microglia/astrocyte pathways and TLR4 signaling in cerebellar pain processing centers. These findings support integrative approaches combining omega-3 supplementation with conventional and complementary therapies, including acupuncture, for comprehensive fibromyalgia treatment protocols.